Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voriconazole intravenous-to-oral switch pharmacokinetic study in hospitalized children for systemic fungal infection prophylaxis
2014-004184-21Phase 2
- Sponsor
- Pfizer
- Start
- May 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of voriconazole in mycoses, sponsored by Pfizer. Primary endpoint: Area under the concentration-time curve over the dosing interval.
02
Drugs
voriconazole
03
Conditions
mycoses
Beyond the preview
Go deeper on 2014-004184-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004184-21.